Document is current

Any future updates will be listed below

244 AFNT-111, a safe and effective TCR-engineered T cell therapy targeting the oncogenic driver KRAS G12V mutation

Crossref DOI link: https://doi.org/10.1136/jitc-2022-SITC2022.0244

Published Online: 2022-11-07

Published Print: 2022-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

About CrossMark